{
    "body": "Is the gene SLC6A2 associated with orthostatic intolerance?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23580201", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12589229", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22723437", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11458707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12391111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15894713", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12805287"
    ], 
    "ideal_answer": [
        "Yes, variants of the SLC6A2 (or NET) gene are associated with orthostatic intolerance."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054971"
    ], 
    "type": "yesno", 
    "id": "56d8ba1851531f7e33000005", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 211, 
            "text": "Orthostatic intolerance is a debilitating syndrome characterized by tachycardia on assumption of upright posture. The norepinephrine (NE) transporter (NET) has been implicated in a genetic form of the disorder. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12391111", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1185, 
            "offsetInEndSection": 1324, 
            "text": "Thus attenuated baroreflex function and reduced sympathetic outflow may contribute to the orthostatic intolerance of severe NET deficiency.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12391111", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 170, 
            "text": "A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12805287", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 174, 
            "offsetInEndSection": 334, 
            "text": " Recently, our laboratory reported a polymorphism in the human NET (hNET) gene A457P in an individual with the autonomic disorder orthostatic intolerance (OI). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12805287", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 348, 
            "offsetInEndSection": 578, 
            "text": "Nonsynonymous single nucleotide polymorphisms (SNPs) in the human NET (hNET) gene that influence transporter function can contribute to disease, such as the nonfunctional transporter, A457P, identified in orthostatic intolerance. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15894713", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 131, 
            "text": "Orthostatic intolerance is not necessarily related to a specific mutation (Ala457Pro) in the human norepinephrine transporter gene.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12589229", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": -1, 
            "offsetInEndSection": 117, 
            "text": "We propose that chromatin-modifying events associated with SLC6A2 gene suppression may constitute a mechanism of POTS.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723437", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 348, 
            "offsetInEndSection": 457, 
            "text": "The goal of the present study was to further characterize the role and regulation of the SLC6A2 gene in POTS.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723437", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1114, 
            "offsetInEndSection": 1383, 
            "text": "In the absence of altered SLC6A2 gene sequence or promoter methylation, this reduced expression was directly correlated with chromatin modifications.  We propose that chromatin-modifying events associated with SLC6A2 gene suppression may constitute a mechanism of POTS.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723437", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 230, 
            "offsetInEndSection": 458, 
            "text": "A coding mutation in the norepinephrine transporter gene (SLC6A2) sequence has been reported in 1 family kindred only. The goal of the present study was to further characterize the role and regulation of the SLC6A2 gene in POTS.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723437", 
            "endSection": "abstract"
        }
    ]
}